PHENERGAN (promethazine hydrochloride) by Thayer Medical is clinical pharmacology promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. First approved in 1956.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
Phenergan (promethazine HCl) is a phenothiazine derivative and H1 receptor antagonist approved in 1956 for injection. It provides antihistaminic, sedative, and antiemetic effects with onset within 20 minutes and duration of 4–12 hours, working through dopamine antagonism (1/10 that of chlorpromazine) and histamine blockade.
As LOE approaches, the brand team is likely contracting; career opportunities center on generic transition planning and defending market share against low-cost competitors.
CLINICAL PHARMACOLOGY Promethazine is a phenothiazine derivative which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. It is thought that this configuration is responsible for its relative lack (1/10 that of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Phenergan offers limited growth trajectory but valuable experience in legacy product management, competitive defense, and generic transition strategy. Career value lies in operational excellence, cost optimization, and market-share protection in a declining branded market.
Worked on PHENERGAN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo